*OT*
Thanks Rick...boy, I can think of several
things that would fit nicely into TKT, but
the silence over on Gene Therapy is deafening.
While I've gotcha here, regarding Sibia, I
sincerely hope it turns out to be a great call,
wouldn't be the first good call...and you even
got post 1000 <g>.
I mentioned that I sold half of mine, not
that I had a lot, but I should think with
the very low volume, and some interest in
trading it (see 13-day moving average thread)
that it could slip a bit more.
I assume you are looking past the PFE threat,
you fellas consider all that to be a red herring,
maybe I was silly to get shook out, but if that
handful of licenses goes, wouldn't the stock get
hit?
And it seems there is a good chance 1508Y and
1553A will not amount to much, hence the LLY deal
giving those away just before data, and I understand
you are in more for 3182 and future nAChRs (and
you pointed out that VGCC program as well.)
Anyway, I'm going to look to buy those shares back
on a dip to $3 soon, damn foolishness to expect that
right?
Here is something I stumbled onto, you might
find it interesting--I did not do a search to
find any papers on this "CRD-NRG" tho.
columbia.edu
CRD-NRG mediates the activity of presynaptic input in inducing
receptor expression. CRD-NRG expression is apparent at the earliest
stages of neuronal differentiation. The induction of specific nAChR
subunits and the enhancement of nAChR-currents by presynaptic input
are selectively blocked by prior exposure of the input to CRD-NRG
specific antisense-oligonucleotides.
Of course this caught my attenion merely because it had antisense/
ODN and nAChR in the same sentence, thought you could have a
gander, or filter this message and send it on to Harry if
you think it is not junk.
Posted this here so the biotechies could find it, without
looking like I was trying to talk it down to traders of sibi,
which would be really lame. Hope I do get the chance to buy it
back a couple bucks cheaper. |
